Merck announced that the company will lay off 170 people from Cambridge, Massachusetts-based Acceleron Pharma, which was acquired during November 2021 for about $11.5 billion.
Japan’s Eisai Co. Ltd. will surrender the company’s rights to share profit from Aduhelm – the Alzheimer’s treatment drug jointly developed with U.S. partner Biogen Inc. – and instead receive sales royalties, the companies said on March 14.
Britain’s GlaxoSmithKline will receive $1.25 billion from Gilead Sciences as part of a settlement between GSK’s HIV medicines unit and the U.S.-based drugmaker, ending a long-drawn patent dispute.
Amgen is partnering with Ann Arbor, Michigan-based EVOQ Therapeutics for a license and collaboration deal to discover and develop drugs for autoimmune disorders.
Relay Therapeutics entered a global license and collaboration agreement with Genentech for the commercialization and development of RLY-1971, a potent inhibitor of SHP2.
Genmab is squaring off with Janssen in a legal battle over royalties from the multiple myeloma drug Darzalex, and shares of the Denmark-based company fell in trading after the announcement.
Bayer secured the rights to an experimental breast cancer drug developed by U.S. biotech firm Systems Oncology LLC in a deal worth up to $370 million.
Acadia Pharmaceuticals is adding a novel pain portfolio to the company’s pipeline through the acquisition of Texas-based CerSci Therapeutics for $52.5 million.
Zymeworks and longtime partner Merck signed a new license agreement. Merck was granted the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms.
In a regulatory filing, Royalty Pharma indicated plans to offer 70 million shares of stock at a target price range of $25 to $28 per share.
